Variation of PPARG Expression in Chemotherapy-Sensitive Patients of Hypopharyngeal Squamous Cell Carcinoma

Table 1

Clinical data of HSCC patients for GSE85608.

Subject ID	Age	TNM stage	Histologic differentiation degree	Chemotherapy response	Gender
S1	69	T4aN2M0	Moderately differentiated	PR	Male
S2	62	T4aN2M0	Well differentiated	PR	Male
S3	69	T4N1M0	Poorly differentiated	PR	Male
S4	49	T3N2M0	Moderately differentiated	PR	Male
S5	60	T4bN2M0	Moderately differentiated	PR	Male
S6	69	T4aN0M0	Moderately differentiated	PR	Male
S7	44	T2N2M0	Poorly differentiated	PR	Male
S8	53	T4aN0M0	Well differentiated	PR	Male
S9	49	T4aN2M0	Moderately differentiated	PR	Male
S10	44	T4aN2M0	Poorly differentiated	PR	Male
S11	60	T3N1M0	Moderately differentiated	CR	Male
S12	48	T4bN2M0	Well differentiated	PR	Male
N1	65	T4aN2M0	Well differentiated	SD	Male
N2	45	T2N3M0	Moderately differentiated	PD	Male
N3	57	T4bN3M1	Well differentiated	SD	Male
N4	69	T3N2M0	Well differentiated	SD	Male
N5	71	T4aN2M0	Poorly differentiated	SD	Male
N6	43	T4bN2M1	Poorly differentiated	SD	Male
N7	69	T2N1M0	Well differentiated	SD	Male
N8	71	T4aN0M0	Well differentiated	SD	Male
N9	43	T4aN2M0	Moderately differentiated	SD	Male

Note: CR (complete response): disappearance; confirmed at 4 weeks; PR (partial response): 50% decrease; confirmed at 4 weeks; SD (stable disease): neither PR nor PD criteria are met; PD (progressive disease): 25% increase; no CR, PR, or SD documented before a progressed disease.